Good News for Genomic Health
Recently, Genomic Health, Inc. (GHDX) announced that it has agreed to
distribute its breast cancer assay Oncotype DX with Palex Medical S.A.
in Spain and Portugal. The company also announced encouraging data on
Oncotype DX at the 7th European Breast Cancer Conference in Barcelona.
The
agreement with Palex Medical, a leading player in the distribution of
medical devices in Spain and Portugal, further expands the
international presence of Genomic Health’s lead product. The
transaction aims to provide physicians and patients with increased
access to this advanced diagnostic test in the European market. More
than 8,000 physicians had ordered in excess of 135,000 Oncotype DX , Elsa Peretti tag pendant, tests in over 55 countries as of December 2009.
In addition to the deal, Genomic Health announced data , Elsa Peretti Open Heart ring,
from 2 studies which further underline the benefits related to Oncotype
DX. Oncotype DX, launched in the US in January 2004, is used for early
stage breast cancer patients to predict the likelihood of cancer
recurrence, the likelihood of patient survival within 10 years of
diagnosis and the likelihood of chemotherapy benefit.
All tumor samples are sent to the company’s laboratory in Redwood City, CA for analysis. Upon generation and delivery of a , Elsa Peretti STARFISH pendant, Recurrence Score report to the physician, the company usually bills third-party payers for Oncotype DX.
In
January 2010, the company diversified its product portfolio by
launching the Oncotype DX colon cancer test worldwide and began
accepting tumor samples. The 12-gene diagnostic test aims to predict
individual recurrence risk in stage II colon cancer patients after
surgery.
The Genomic Health test is the first multigene
expression test developed for assessing the risk of recurrence in
patients suffering from stage II colon cancer. We believe that Genomic
Health can be a useful player in the colon cancer market in addition to
the , Elsa Peretti MINI BEAN earrings,
breast cancer market. Moreover, the colon cancer test will reduce the
company’s dependence on the breast cancer assay for generating revenues.
We are currently Neutral on Genomic Health.
Commentaires
Il n'y a aucun commentaire sur cet article.